3′Nucleotidase/nuclease is required for Leishmania infantum clinical isolate susceptibility to miltefosine

Detalhes bibliográficos
Autor(a) principal: Carniellie, Juliana
Data de Publicação: 2022
Outros Autores: Dave, Anuja, Romano, Audrey, Forrester, Sarah, Faria, Pedro, Renata, Monti-Rocha, Costa, Carlos, Dietze, R, Graham, Ian, Mottram, Jeremy C.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10362/147810
Resumo: Summary Background Miltefosine treatment failure in visceral leishmaniasis in Brazil has been associated with deletion of the miltefosine susceptibility locus (MSL) in Leishmania infantum. The MSL comprises four genes, 3′ -nucleotidase/nucleases (NUC1 and NUC2); helicase-like protein (HLP); and 3,2-trans-enoyl-CoA isomerase (TEI). Methods In this study CRISPR-Cas9 was used to either epitope tag or delete NUC1, NUC2, HLP and TEI, to investigate their role in miltefosine resistance mechanisms. Additionally, miltefosine transporter genes and miltefosine-mediated reactive oxygen species homeostasis were assessed in 26 L. infantum clinical isolates. A comparative lipidomic analysis was also performed to investigate the molecular basis of miltefosine resistance. Findings Deletion of both NUC1, NUC2 from the MSL was associated with a significant decrease in miltefosine susceptibility, which was restored after re-expression. Metabolomic analysis of parasites lacking the MSL or NUC1 and NUC2 identified an increase in the parasite lipid content, including ergosterol; these lipids may contribute to miltefosine resistance by binding the drug in the membrane. Parasites lacking the MSL are more resistant to lipid metabolism perturbation caused by miltefosine and NUC1 and NUC2 are involved in this pathway. Additionally, L. infantum parasites lacking the MSL isolated from patients who relapsed after miltefosine treatment were found to modulate nitric oxide accumulation in host macrophages. Interpretation Altogether, these data indicate that multifactorial mechanisms are involved in natural resistance to miltefosine in L. infantum and that the absence of the 3’nucleotidase/nuclease genes NUC1 and NUC2 contributes to the phenotype.
id RCAP_6aaa00f240766f711633e1505146cd6d
oai_identifier_str oai:run.unl.pt:10362/147810
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling 3′Nucleotidase/nuclease is required for Leishmania infantum clinical isolate susceptibility to miltefosineMiltefosine resistanceVisceral leishmaniasisCRISPR-Cas9;3’nucleotidase/nucleasePrognostic markerRM Therapeutics. PharmacologyQ ScienceQR MicrobiologyApplied Microbiology and BiotechnologyParasitologyGeneticsMolecular BiologySDG 3 - Good Health and Well-beingSummary Background Miltefosine treatment failure in visceral leishmaniasis in Brazil has been associated with deletion of the miltefosine susceptibility locus (MSL) in Leishmania infantum. The MSL comprises four genes, 3′ -nucleotidase/nucleases (NUC1 and NUC2); helicase-like protein (HLP); and 3,2-trans-enoyl-CoA isomerase (TEI). Methods In this study CRISPR-Cas9 was used to either epitope tag or delete NUC1, NUC2, HLP and TEI, to investigate their role in miltefosine resistance mechanisms. Additionally, miltefosine transporter genes and miltefosine-mediated reactive oxygen species homeostasis were assessed in 26 L. infantum clinical isolates. A comparative lipidomic analysis was also performed to investigate the molecular basis of miltefosine resistance. Findings Deletion of both NUC1, NUC2 from the MSL was associated with a significant decrease in miltefosine susceptibility, which was restored after re-expression. Metabolomic analysis of parasites lacking the MSL or NUC1 and NUC2 identified an increase in the parasite lipid content, including ergosterol; these lipids may contribute to miltefosine resistance by binding the drug in the membrane. Parasites lacking the MSL are more resistant to lipid metabolism perturbation caused by miltefosine and NUC1 and NUC2 are involved in this pathway. Additionally, L. infantum parasites lacking the MSL isolated from patients who relapsed after miltefosine treatment were found to modulate nitric oxide accumulation in host macrophages. Interpretation Altogether, these data indicate that multifactorial mechanisms are involved in natural resistance to miltefosine in L. infantum and that the absence of the 3’nucleotidase/nuclease genes NUC1 and NUC2 contributes to the phenotype.Instituto de Higiene e Medicina Tropical (IHMT)Individual Health Care (IHC)Global Health and Tropical Medicine (GHTM)Universidade NOVA de LisboaRUNCarniellie, JulianaDave, AnujaRomano, AudreyForrester, SarahFaria, PedroRenata, Monti-Rocha,Costa, CarlosDietze, RGraham, IanMottram, Jeremy C.2023-01-18T22:17:05Z20222022-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10362/147810eng2352-3964PURE: 50622397https://doi.org/10.1016/j.ebiom.2022.104378info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-03-11T05:29:03Zoai:run.unl.pt:10362/147810Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T03:53:05.379140Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv 3′Nucleotidase/nuclease is required for Leishmania infantum clinical isolate susceptibility to miltefosine
title 3′Nucleotidase/nuclease is required for Leishmania infantum clinical isolate susceptibility to miltefosine
spellingShingle 3′Nucleotidase/nuclease is required for Leishmania infantum clinical isolate susceptibility to miltefosine
Carniellie, Juliana
Miltefosine resistance
Visceral leishmaniasis
CRISPR-Cas9;
3’nucleotidase/nuclease
Prognostic marker
RM Therapeutics. Pharmacology
Q Science
QR Microbiology
Applied Microbiology and Biotechnology
Parasitology
Genetics
Molecular Biology
SDG 3 - Good Health and Well-being
title_short 3′Nucleotidase/nuclease is required for Leishmania infantum clinical isolate susceptibility to miltefosine
title_full 3′Nucleotidase/nuclease is required for Leishmania infantum clinical isolate susceptibility to miltefosine
title_fullStr 3′Nucleotidase/nuclease is required for Leishmania infantum clinical isolate susceptibility to miltefosine
title_full_unstemmed 3′Nucleotidase/nuclease is required for Leishmania infantum clinical isolate susceptibility to miltefosine
title_sort 3′Nucleotidase/nuclease is required for Leishmania infantum clinical isolate susceptibility to miltefosine
author Carniellie, Juliana
author_facet Carniellie, Juliana
Dave, Anuja
Romano, Audrey
Forrester, Sarah
Faria, Pedro
Renata, Monti-Rocha,
Costa, Carlos
Dietze, R
Graham, Ian
Mottram, Jeremy C.
author_role author
author2 Dave, Anuja
Romano, Audrey
Forrester, Sarah
Faria, Pedro
Renata, Monti-Rocha,
Costa, Carlos
Dietze, R
Graham, Ian
Mottram, Jeremy C.
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Instituto de Higiene e Medicina Tropical (IHMT)
Individual Health Care (IHC)
Global Health and Tropical Medicine (GHTM)
Universidade NOVA de Lisboa
RUN
dc.contributor.author.fl_str_mv Carniellie, Juliana
Dave, Anuja
Romano, Audrey
Forrester, Sarah
Faria, Pedro
Renata, Monti-Rocha,
Costa, Carlos
Dietze, R
Graham, Ian
Mottram, Jeremy C.
dc.subject.por.fl_str_mv Miltefosine resistance
Visceral leishmaniasis
CRISPR-Cas9;
3’nucleotidase/nuclease
Prognostic marker
RM Therapeutics. Pharmacology
Q Science
QR Microbiology
Applied Microbiology and Biotechnology
Parasitology
Genetics
Molecular Biology
SDG 3 - Good Health and Well-being
topic Miltefosine resistance
Visceral leishmaniasis
CRISPR-Cas9;
3’nucleotidase/nuclease
Prognostic marker
RM Therapeutics. Pharmacology
Q Science
QR Microbiology
Applied Microbiology and Biotechnology
Parasitology
Genetics
Molecular Biology
SDG 3 - Good Health and Well-being
description Summary Background Miltefosine treatment failure in visceral leishmaniasis in Brazil has been associated with deletion of the miltefosine susceptibility locus (MSL) in Leishmania infantum. The MSL comprises four genes, 3′ -nucleotidase/nucleases (NUC1 and NUC2); helicase-like protein (HLP); and 3,2-trans-enoyl-CoA isomerase (TEI). Methods In this study CRISPR-Cas9 was used to either epitope tag or delete NUC1, NUC2, HLP and TEI, to investigate their role in miltefosine resistance mechanisms. Additionally, miltefosine transporter genes and miltefosine-mediated reactive oxygen species homeostasis were assessed in 26 L. infantum clinical isolates. A comparative lipidomic analysis was also performed to investigate the molecular basis of miltefosine resistance. Findings Deletion of both NUC1, NUC2 from the MSL was associated with a significant decrease in miltefosine susceptibility, which was restored after re-expression. Metabolomic analysis of parasites lacking the MSL or NUC1 and NUC2 identified an increase in the parasite lipid content, including ergosterol; these lipids may contribute to miltefosine resistance by binding the drug in the membrane. Parasites lacking the MSL are more resistant to lipid metabolism perturbation caused by miltefosine and NUC1 and NUC2 are involved in this pathway. Additionally, L. infantum parasites lacking the MSL isolated from patients who relapsed after miltefosine treatment were found to modulate nitric oxide accumulation in host macrophages. Interpretation Altogether, these data indicate that multifactorial mechanisms are involved in natural resistance to miltefosine in L. infantum and that the absence of the 3’nucleotidase/nuclease genes NUC1 and NUC2 contributes to the phenotype.
publishDate 2022
dc.date.none.fl_str_mv 2022
2022-01-01T00:00:00Z
2023-01-18T22:17:05Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10362/147810
url http://hdl.handle.net/10362/147810
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 2352-3964
PURE: 50622397
https://doi.org/10.1016/j.ebiom.2022.104378
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799138122306420736